AFP.AX

Healthcare Drug Manufacturers - Specialty & Generic

AFT Pharmaceuticals Limited

A$3.45

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

361.79M

Avg Volume

1,784

P/E (TTM)

31.36

EPS

A$0.11

52W High

A$4.13

52W Low

A$2.45

Div. Yield

0.7%

Valuation

Forward P/E

21.21

P/B Ratio

4.05

P/S Ratio

1.42

EV/EBITDA

16.26

EV/Revenue

1.59

Margins

Gross Margin 43.4%

Operating Margin 14.1%

Net Margin 5.8%

EBITDA Margin 9.8%

Growth & Returns

Revenue Growth (YoY)

15.2%

Earnings Growth (YoY)

(16.5%)

Earnings Growth (QoQ)

(19.2%)

Return on Equity

13.7%

Return on Assets

7.9%

Liquidity & Leverage

Current Ratio

2.24

Quick Ratio

1.03

Debt / Equity

0.50

Total Cash

10.24M

Total Debt

54.11M

About

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration with Hyloris Pharmaceuticals SA for the development of the Maxigesic IV product. AFT Pharmaceuticals Limited was incorporated in 1997 and is headquartered in Auckland, New Zealand.